S
Sinem Nihal Esatoglu
Researcher at Istanbul University
Publications - 64
Citations - 758
Sinem Nihal Esatoglu is an academic researcher from Istanbul University. The author has contributed to research in topics: Medicine & Infliximab. The author has an hindex of 11, co-authored 58 publications receiving 493 citations. Previous affiliations of Sinem Nihal Esatoglu include University of Health Sciences Antigua.
Papers
More filters
Journal ArticleDOI
Performance of pneumonia severity index and CURB-65 in predicting 30-day mortality in patients with COVID-19.
Celal Satici,Mustafa Asim Demirkol,Elif Sargin Altunok,Bengul Gursoy,Mustafa Alkan,Sadettin Kamat,Berna Demirok,Cemile Dilsah Surmeli,Mustafa Calik,Zuhal Cavus,Sinem Nihal Esatoglu +10 more
TL;DR: In a large group of hospitalized patients with COVID-19, it was found that PSI performed better than CURB-65 in predicting mortality, and higher CRP levels were associated with an increased risk for mortality.
Journal ArticleDOI
Management of major organ involvement of Behçet’s syndrome: a systematic review for update of the EULAR recommendations
Yesim Ozguler,Pietro Leccese,Robin Christensen,Robin Christensen,Sinem Nihal Esatoglu,Dongsik Bang,Bahram Bodaghi,Aykut Ferhat Celik,Farida Fortune,Julien Gaudric,Ahmet Gül,Ina Kötter,Alfred Mahr,Robert J. Moots,Jutta G Richter,David Saadoun,Carlo Salvarani,Francesco Scuderi,Petros P. Sfikakis,Aksel Siva,Miles Stanford,Ilknur Tugal-Tutkun,Richard P. West,Sebahattin Yurdakul,Ignazio Olivieri,Hasan Yazici,Gulen Hatemi +26 more
TL;DR: The majority of studies related to major organ involvement that informed the updated EULAR recommendations for the management of BS were observational studies, including studies with beneficial results for refractory uveitis.
Journal ArticleDOI
Characteristics, Treatment, and Long-Term Outcome of Gastrointestinal Involvement in Behcet's Syndrome: A Strobe-Compliant Observational Study From a Dedicated Multidisciplinary Center.
Ibrahim Hatemi,Sinem Nihal Esatoglu,Gulen Hatemi,Yusuf Erzin,Hasan Yazici,Aykut Ferhat Celik +5 more
TL;DR: Azathioprine seems to be a good choice as first-line treatment with high remission rates and few adverse events, and Thalidomide and/or TNF-alpha antagonists may be preferred in resistant cases.
Journal ArticleDOI
Management of skin, mucosa and joint involvement of Behcet's syndrome: A systematic review for update of the EULAR recommendations for the management of Behcet's syndrome
Pietro Leccese,Yesim Ozguler,Robin Christensen,Sinem Nihal Esatoglu,Dongsik Bang,Bahram Bodaghi,Aykut Ferhat Celik,Farida Fortune,Julien Gaudric,Ahmet Gül,Ina Kötter,Alfred Mahr,Robert J. Moots,Jutta G Richter,David Saadoun,Carlo Salvarani,Francesco Scuderi,Petros P. Sfikakis,Aksel Siva,Miles Stanford,Ilknur Tugal-Tutkun,Richard P. West,Sebahattin Yurdakul,Ignazio Olivieri,H. Yazici,Gulen Hatemi +25 more
TL;DR: RCTs comprised more than a half (21/37, 57%) of the sources included in the evidence synthesis related to skin, mucosa and joint involvement applicable for the EULAR Recommendations for the management of BS.
Journal ArticleDOI
Update on the treatment of Behçet's syndrome
TL;DR: Tumor necrosis factor alpha inhibitors, especially infliximab and adalimumab, are increasingly used for various refractory BS manifestations despite the lack of controlled studies.